ESMO 2024 Roundup: A Lot Of Stumbles, But There Are New Signs Of Life
The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...
Business Insider6d
Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer
The ESMO Proferred Paper Oral Presentation slides are available on the Posters & Publications ... in combination with MSD’s ...
Pharmabiz5d
Cytovation to present safety and efficacy data from CICILIA phase I/IIa clinical trial evaluating CY-101 in solid tumors
Cytovation to present safety and efficacy data from CICILIA phase I/IIa clinical trial evaluating CY-101 in solid tumors: Bergen, Norway Monday, September 16, 2024, 18:00 Hrs [IST ...
PDS Biotech Announces Updated Results From VERSATILE-002 Phase 2 Clinical Trial Presented At ESMO 2024
PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the“Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the ...
Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01
Overall Response Rate15 out of the 16 patients had a reduction of their tumors (target lesions)79% of EVX-01’s vaccine targets triggered a targeted immune response, which compares very favorably to ...
Stockhouse5d
Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01
s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with advanced melanoma (skin cancer). The data was presented during the weekend at a poster ...
Le Lézard3d
New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis
Bristol Myers Squibb today announced new data from the Phase 3 DAYBREAK trial demonstrating that decreased rates of brain volume loss were sustained in the open-label extension (OLE) for patients ...
AZoRobotics on MSN4d
Evaxion Biotech Reports Positive One-Year Results for AI-Designed Cancer Vaccine
Evaxion Biotech A/S, a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, announces ...
BioSpace6d
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer
The poster can be found on the “Posters & Publications ... IO Biotech is sponsoring the Phase 2 trial and Merck is supplying pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103 ...
PipelineReview.com5d
Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01
Merck Sharp & Dohme LLC supplies KEYTRUDA ® (pembrolizumab) for the trial ... The data was presented during the weekend at a poster session at the European Society for Medical Oncology (ESMO) Congress ...